Cirrhosis is more common than most people realize. Globally, over 2 million new cases are diagnosed each year, translating to roughly 25 per 100,000 people. In the United States, about 4.5 million adults (1.8% of the adult population) are living with diagnosed liver disease, and a significant portion of those cases involve cirrhosis. The true numbers are likely higher, because cirrhosis often develops silently and goes undetected for years.
Global and U.S. Numbers
Between 1990 and 2019, the total number of cirrhosis cases worldwide grew by more than 700,000, surpassing 2 million annual cases by 2019. The rate per person, however, has held relatively steady or even ticked down slightly, from 25.7 per 100,000 in 1990 to 25.3 in 2019. That seeming contradiction comes down to population growth: more people on the planet means more total cases even when the per-person risk stays flat.
Geography matters enormously. Central Asia has one of the highest rates in the world at roughly 59 per 100,000, while parts of Oceania sit as low as 8.5 per 100,000. In the U.S., cirrhosis-related mortality has been climbing, particularly among middle-aged adults. Deaths from chronic liver disease and cirrhosis among people aged 45 to 64 increased 31% between 2000 and 2015.
Cirrhosis also kills at a staggering global scale. In 2021, approximately 1.43 million people worldwide died from cirrhosis-related causes, up from 1.02 million in 1990.
What Causes Most Cases
The leading causes of cirrhosis have shifted dramatically over the past two decades. Hepatitis C used to dominate. In 2000, it accounted for roughly 45% of new cirrhosis cases in some cohorts. Thanks to effective antiviral treatments, that share had dropped to about 11% by 2019.
Fatty liver disease tied to obesity and metabolic conditions (sometimes called MASLD or NAFLD) has taken its place. It rose from causing around 14% of new cases in 2000 to 36% in 2019, making it the single most common driver of cirrhosis in many countries. Alcohol-related liver disease remains the second leading cause, responsible for roughly 24 to 33% of cases depending on the population studied. Some people have more than one contributing factor, such as heavy drinking combined with obesity.
Who Is Most Affected
Cirrhosis rates rise with age, and the disease hits men harder than women overall. But the gap is narrowing. Between 2000 and 2015, death rates among U.S. women aged 45 to 64 jumped 57%, compared to 21% for men in the same age group. Among younger women (25 to 44), mortality rose 18%, while it actually fell 10% for men in that bracket. Rising rates of alcohol use and obesity among women are likely contributors.
Racial and ethnic background also plays a role, at least in the United States. For alcohol-related liver disease specifically, Hispanic Americans have the highest prevalence at about 4.5%, compared to 3.1% for white Americans and 1.4% for Black Americans. Hispanic individuals are roughly 64% more likely than white individuals to develop alcohol-related liver disease, though once the disease is present, mortality rates across racial groups are broadly similar.
Many Cases Go Undiagnosed
One of the most striking aspects of cirrhosis is how quietly it develops. The liver can lose a substantial amount of function before symptoms appear, and routine blood tests don’t always catch early-stage scarring. Research on patients diagnosed with liver cancer found that about 39% of those who had underlying cirrhosis didn’t know about it until the cancer was discovered. Other U.S. estimates suggest that anywhere from 22% to 50% of cirrhosis cases may be unrecognized at the time a serious complication appears.
When cirrhosis is caught early, it’s typically in what’s called the “compensated” stage, meaning the liver is scarred but still functioning well enough to keep symptoms at bay. In one long-term study, about 69% of patients were in this compensated stage at diagnosis, while 31% were already decompensated, meaning they had developed complications like fluid buildup, confusion from toxin accumulation, or internal bleeding. The stage at diagnosis has a major impact on outlook, which is why the high rate of undiagnosed cases is concerning.
Projected Growth From Obesity and Diabetes
The outlook for the next decade is not encouraging. Because obesity and type 2 diabetes continue to rise worldwide, researchers project steep increases in cirrhosis caused by fatty liver disease. Modeling studies covering eight major countries, including the U.S., the U.K., and China, estimate that compensated cirrhosis from fatty liver disease will increase by 64% to 156% by 2030, depending on the country. Decompensated cases, the more dangerous stage, are projected to rise by 75% to 187%.
In parts of Asia, the trend is similar. Projections for Hong Kong, South Korea, Singapore, and Taiwan estimate that new cases of advanced fatty liver cirrhosis will increase by 65% to 100% between 2019 and 2030. These projections reinforce that cirrhosis is becoming less of an “alcohol and hepatitis” disease and more of a metabolic one, closely tied to the same lifestyle factors driving heart disease and diabetes.
The Economic Weight
Cirrhosis is expensive to manage. Total U.S. healthcare spending on cirrhosis and chronic liver disease reached $32.5 billion in 2016, growing at about 4.3% per year over the prior two decades. When you zoom in on fatty liver disease alone, the direct medical costs in the United States run around $103 billion annually, averaging roughly $1,600 per patient per year. These figures include hospitalizations, medications, transplant evaluations, and treatment of complications. They don’t capture the full picture of lost income and reduced productivity from a disease that increasingly strikes working-age adults.